What Johnson & Johnson's Quarter ended Sep 27, 2026 10-Q says: 8 signals
Johnson & Johnson filed its latest 10-Q with the SEC on Oct 21, 2026. It discusses acquisition completed, digital transformation and goodwill impairment.
Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API
What changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.- Filed
- Oct 21, 2026
- Period
- Quarter ended Sep 27, 2026
- Filings
- 3
- Signals
- 20
Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated
10-Q · latest 10
What Johnson & Johnson's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 27, 2026
Filed · 8 signals
Recorded $5.5 billion charge for proposed talc ovarian litigation resolution
Johnson & Johnson recorded a charge of approximately $5.5 billion in Q3 and the fiscal nine months of 2026 related to the proposed talc ovarian litigation resolution.
$5.5B
charge related to proposed talc ovarian litigation resolution
Johnson & Johnson plans to separate Orthopaedics business by mid-2027
The Company announced its intention to separate its Orthopaedics business and expects the separation to be completed in mid-2027.
The Company is executing a multi-year, enterprise-wide initiative to standardize and simplify systems across human resources, IT, procurement, supply chain, and finance functions to support financial shared services capabilities.
financial systems
J&J records $1.0 billion IPR&D charge for Firefly Bio acquisition
Johnson & Johnson incurred an acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly Bio, Inc.
$1B
acquired in-process research and development expense related to the acquisition of Firefly Bio, Inc.
Recorded $0.4 billion impairment charge for non-strategic PreCardia asset
The company recorded an in-process research and development impairment charge of approximately $0.4 billion in the fiscal nine months of 2026, primarily related to PreCardia.
$400M
charge primarily related to PreCardia asset impairment
Pre-tax margin compressed significantly to 0.1% of sales in Q3 2026
Consolidated earnings before provision for taxes dropped to $34.0 million (0.1% of sales) in Q3 2026 from $7.5 billion (31.2% of sales) in Q3 2025, driven by litigation and acquired IPR&D charges.
$34M
earnings before provision for taxes on income in Q3 2026
0.1%
earnings before provision for taxes on income as a percent of sales in Q3 2026
International sales grew 6.2% to $31.9 billion in fiscal nine months 2026
Sales by international companies reached $31.9 billion for the fiscal nine months, up 6.2% total with operational growth of 3.0%.
$31.9B
sales by international companies in the fiscal nine months of 2026
6.2%
increase in international company sales compared to prior year
- SEC EDGAR
10-Q · Quarter ended Jun 28, 2026
Filed · 6 signals
Johnson & Johnson advancing planned separation of Orthopaedics business within 18 to 24 months
Johnson & Johnson is pursuing multiple paths to complete the separation of its Orthopaedics franchise within 18 to 24 months of its October 2025 announcement, having incurred $0.4 billion in separation costs in the first six months of 2026.
Johnson & Johnson is executing a multi-year, enterprise-wide project to standardize and integrate processes across HR, IT, procurement, supply chain, and finance to support financial shared services.
financial systems
Recorded $0.8B in litigation charges for talc matters during first half of 2026
The company recorded charges of $0.8 billion related to talc litigation matters in the fiscal six months of 2026, with $0.3 billion recorded in Q2.
$800M
charges for talc litigation matters
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 29, 2026Filed · 6 signalsSEC EDGAR
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Johnson & Johnson earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Worldwide sales rise 6% to $25.4B, exceeding consensusWorldwide sales reached $25.4 billion in Q3 2026, representing operational growth of 6.0%. Growth was driven by 9.1% expansion in the U.S. and 1.8% outside the U.S., placing the company on track to surpass $100 billion in full-year revenue for the first time. | |
| Raised 2026 operational sales guidance to $100.7B midpointFull-year 2026 operational sales guidance was raised to 6.7%-7.1%, representing $100.7 billion at the midpoint (6.9% growth). Reported sales growth is projected at 7.2%-7.6% ($101.2 billion midpoint), with adjusted operational EPS guidance raised to $10.95-$11.05. | |
| Completed $1B acquisition of Firefly Bio for oncologyThe company completed the acquisition of Firefly Bio, deploying $1 billion to acquire its degrader antibody conjugate platform targeting difficult-to-treat cancer drivers such as KRAS. The transaction impacted Q3 adjusted and GAAP earnings by approximately $1 billion in acquired IPR&D. | |
| Innovative Medicine sales grow 7.9% to $16.8BInnovative Medicine posted worldwide sales of $16.8 billion, expanding 7.9% operationally with U.S. growth of 11.1%. Performance was led by oncology up approximately 17%, including DARZALEX growing 15.6% and TREMFYA jumping 68.2% across immunology indications. | |
| Received FDA de novo authorization for OTTAVA robotic systemThe U.S. FDA granted de novo clearance for OTTAVA, a soft-tissue robotic surgery system connected to the Polyphonic digital ecosystem. The company secured its first commercial customer and initiated an investigational device exemption trial in inguinal hernia repair. | |
| VARIPULSE Pro approved in Japan, driving European expansionVARIPULSE Pro received regulatory approval in Japan following strong commercial traction and double-digit growth in Europe. The company is preparing for an impending U.S. commercial launch by the end of 2026 for the pulsed field ablation catheter. |
Signal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Johnson & Johnson 10-Q
When did Johnson & Johnson file its latest 10-Q?
What did Johnson & Johnson disclose in its latest 10-Q?
What did Johnson & Johnson say on its recent earnings calls?
Where can I read Johnson & Johnson's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .